FDA Accepts BLA for Fixed-Dose Subcutaneous Combination in HER2-Positive Breast Cancer

The FDA accepted a biologics license application for the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with IV chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer.

Source: CancerNetwork - February 25, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news